OncoMatch

OncoMatch/Colorectal Cancer (CRC)/MSH2

Colorectal Cancer (CRC)MSH2 Clinical Trials

37 recruiting trials·Updated daily from ClinicalTrials.gov

MSH2 is one of four mismatch repair proteins assessed by IHC; loss of MSH2 defines deficient MMR (dMMR) and predicts MSI-H status, qualifying patients for checkpoint immunotherapy. dMMR CRC responds dramatically to PD-1 blockade — pembrolizumab is first-line standard for dMMR metastatic CRC. Trials explore neoadjuvant immunotherapy, combination checkpoint approaches, and MSI as a predictive biomarker across treatment lines.

Match trials to my profileClinician mode →
Top recruiting

Top recruiting MSH2 Colorectal Cancer (CRC) trials

Ranked by phase and US site count.

See all trials matched to your profile →
Phase 3

Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer

National Cancer Institute, Naples

Phase 2/Phase 3

Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer

Centre Hospitalier Universitaire de Besancon

Phase 3

mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC

Jun Huang

Phase 2/Phase 3

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

Sun Yat-sen University

Phase 3

PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer

Sun Yat-sen University

Phase 1/Phase 213 US sites

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Marengo Therapeutics, Inc.

Additional trials

More MSH2 Colorectal Cancer (CRC) trials

See all in search →
Phase 2
NCT04165772Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid TumorsPhase 210 US sitesNCT06992258A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal CancerPhase 29 US sitesNCT07140679Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon CancerPhase 25 US sitesNCT07811193A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or RectumPhase 24 US sitesNCT06529523Tislelizumab in People With Colorectal CancerPhase 21 US siteNCT06959550Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal CancerPhase 21 US siteNCT05411718A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch SyndromePhase 21 US site
17 international trials (no US sites)
NCT06923345Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)Phase 2NCT06567782A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon CancerPhase 2NCT07279077Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Single-Arm, Phase II TrialPhase 2NCT04920149Mesalamine for Colorectal Cancer Prevention Program in Lynch SyndromePhase 2NCT06856837- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver MetastasesPhase 2NCT07841236ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon CancerPhase 2NCT07347951A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal CancerPhase 2NCT06698757Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal CancerPhase 2NCT06911684Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.Phase 2NCT05771181Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer PatientsPhase 2NCT06580574Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon CancersPhase 2NCT07068763Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal CancerPhase 2NCT06002789Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCCPhase 2NCT06722183Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor EntitiesPhase 2NCT05954429A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 StudyPhase 2NCT05310643Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRCPhase 2NCT06949111Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）Phase 2
Other Colorectal Cancer (CRC) biomarkers

Browse other molecular targets with active Colorectal Cancer (CRC) trials.

KRASNRASBRAFMMR / MSI-HMSH6PMS2MLH1HER2 (ERBB2)EGFR
← All Colorectal Cancer (CRC) clinical trials